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Boston, Massachusetts; Campinas, São Paulo, Brazil; and Montreal, Quebec, CanadaOBJECTIVES This study aimed to test the characteristics of the myocardial extracellular volume
fraction (ECV) derived from pre- and post-contrast T1 measurements among healthy volunteers.
BACKGROUND Cardiac magnetic resonance (CMR) T1 measurements of myocardium and blood
before and after contrast allow quantiﬁcation of the ECV, a tissue parameter that has been shown to
change in proportion to the connective tissue fraction.
METHODS Healthy volunteers underwent standard CMR imaging with administration of gadolinium.
T1 measurements were performed with a Look-Locker sequence followed by gradient-echo acquisition.
We tested the segmental, interslice, inter-, intra-, and test-retest characteristics of the ECV, as well as the
association of the ECV with other variables. Juvenile and aged mice underwent a similar protocol, and
cardiac sections were harvested for measurement of ﬁbrosis.
RESULTS In healthy volunteers (N ¼ 32, 56% female; age 21 to 72 years), the ECV averaged 0.28 
0.03 (range 0.23 to 0.33). The intraclass coefﬁcients for the intraobserver, interobserver, and test-retest
absolute agreements of the ECV were 0.94 (95% conﬁdence interval: 0.84 to 0.98), 0.93 (95%
conﬁdence interval: 0.80 to 0.98), and 0.95 (95% conﬁdence interval: 0.52 to 0.99), respectively. In
volunteers, the ECV was associated with age (r ¼ 0.74, p < 0.001), maximal left atrial volume index
(r ¼ 0.67, p < 0.001), and indexed left ventricular mass. There were no differences in the ECV
between segments in a slice or between slices. In mice (N ¼ 12), the myocardial ECV ranged from
0.20 to 0.32 and increased with age (0.22  0.02 vs. 0.30  0.02, juvenile vs. aged mice, p < 0.001).
In mice, the ECV correlated with the extent of myocardial ﬁbrosis (r ¼ 0.94, p < 0.001).
CONCLUSIONS In healthy volunteers, the myocardial ECV ranges from 0.23 to 0.33, has acceptable
test characteristics, and is associated with age, left atrial volume, and left ventricular mass. In mice, the
ECV also increases with age and strongly correlates with the extent of myocardial ﬁbrosis. (J Am Coll
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673he presence of focal myocardial ﬁbrosis is
associated with adverse cardiovascular out-
comes (1 3). Various imaging techniques
have emerged to quantify myocardial ﬁbrosis
noninvasively. Cardiac magnetic resonance (CMR)
with late gadolinium enhancement (LGE) is the
current optimal noninvasive technique for detection
and quantiﬁcation of myocardial scar and replace-
ment ﬁbrosis (4). However, limitations exist to
LGE-based techniques for the detection of diffuse
or interstitial myocardial ﬁbrosis. Comparison with
pathological standards reveals a marked consistentSee page 684
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CI = conﬁdence interval
CMR = cardiac magnetic
resonance
ECV = extracellular volume
fraction
LGE = late gadolinium
enhancement
LV = left ventricular
MOLLI = modiﬁed Lock-Locker
inversion recovery
ShMOLLI = shortened modiﬁed
Lock-Locker inversion recoveryunderestimation of both the presence and extent of
diffuse ﬁbrosis (5 7). The LGE technique relies on
relative enhancement of an abnormal region of
myocardium compared with a normal reference. In
conditions such as hypertension, sleep apnea,
valvular disease, diabetes, obesity, and nonischemic
cardiomyopathy, the entire left ventricle may be
affected by adverse tissue remodeling, and a normal
myocardial reference region may be inappropriately
identiﬁed. Furthermore, the optimal threshold for
quantifying LGE in the presence of diffuse or pat-
chy ﬁbrosis is not well deﬁned (8). These limitations
have prompted research into novel CMR-based
quantitative techniques for measurement of the
myocardial extracellular volume fraction (ECV).
The myocardial ECV increases in proportion to
the connective tissue fraction and can be regarded as
a continuous measurement of the extent of accu-
mulation of myocardial ﬁbrosis (9 11). T1 mapping
is a novel CMR-based technique in which measured
differences in R1 (¼ 1/T1) values before and after
gadolinium allow quantiﬁcation of myocardial ECV
(9,12 15). The CMR T1 technique has the po-
tential to differentiate myocardial ﬁbrosis on a
continuous scale, from normal myocardium,
through diffuse myocardial ﬁbrosis, and ultimately
to myocardial scar (16,17). However, limited data
exist on the myocardial ECV in a normal healthy
population, on the test characteristics of this
evolving technique, the optimal CMR protocol for
measurement of the myocardial ECV, and on thepreviously by an NIH T32 Training Grant (T32HL09430101A1). Dr. Mon
Heart Institute Foundation, Montreal, Canada. Dr. Kwong receives salary s
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other authors have reported that they have no relationships relevant to the con
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Manuscript received June 11, 2012; revised manuscript received September 24associations between the ECV and other clinical
and imaging variables. Thus, our aims were 2-fold.
We ﬁrst wanted to deﬁne a normal reference range
in a healthy population, as well as deﬁne the test
characteristics of the myocardial ECV measure-
ment. The second aim was to test our hypothesis
that the myocardial ECV measurement is associated
with histological evidence of myocardial ﬁbrosis.METHODS
Study protocol. The protocol was approved by
the Partners Healthcare System Human Subjects
Review Committee in the Brigham and Women’s
Hospital. We recruited healthy volunteer controls by
open enrollment.We speciﬁcally excluded volunteers
with chest pain on exertion; any active or prior history
of heart disease, stroke, diabetes, malignancy, sleep
apnea, hypertension, an irregular heart rhythm or
atrial ﬁbrillation; or any form of kidney
disease. Screening consisted of a compre-
hensive questionnaire detailing medical and
medication history, standard anthropo-
metric data, and measurement of blood
pressure, pulse, serum creatinine, and
hematocrit.
To determine whether aging was associ-
ated with a change in the myocardial ECV
in mice and to assess whether aging was
associated with a change in the extent of
myocardial ﬁbrosis, we performed the
following protocol in juvenile and aged
mice. Juvenile C57BL/6 aged 4 weeks (n¼
4) and agedC57BL/6 aged 48weeks (n¼ 8)
underwent aCMRstudy.After theCMRstudy,mice
were euthanized, and cardiac sections were analyzed
for the presence ofmyocardial ﬁbrosis usingMasson’s
trichrome. Serumhematocrit was recorded on the day
mice were killed immediately after the CMR study.
The protocol was approved by the Institutional An-
imalCare andUseCommittee atHarvardUniversity.
Human CMR protocol. All images were acquired
with electrocardiographic gating, breath-holding,
and the patient in a supine position. Patients were
imaged on 3.0-T CMR system (Tim Trio,
Siemens, Erlangen, Germany). The basic CMRgeon receives ﬁnancial support for research from the Montreal
upport from a research grant from the National Institutes of
a research grant from the National Institutes of Health
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674protocol consisted of cine steady-state free-preces-
sion imaging (TR, 3.4 ms; TE, 1.2 ms; in-plane
spatial resolution, 1.6  2 mm) for left ventricular
(LV) function and LV mass. Cine imaging was
obtained in 8 to 14 matching short-axis (8 mm
thick with no gap) and 3 radial long-axis planes.
For the calculation of LV mass and function, the
endocardial and epicardial borders of the LV
myocardium were manually traced on successive
short-axis cine images at end-diastole and systole.
The papillary muscles were excluded in the LV
mass calculation (18), and the LV mass calculation
was then indexed to body surface area (19). Left
atrial systolic and diastolic volumes were measured
using the biplane method as previously described
(20). All patients underwent an LGE imaging
protocol (TR, 4.8 ms; TE, 1.3 ms; inversion time,
200 to 300 ms) to detect focal myocardial ﬁbrosis.
A segmented inversion-recovery pulse sequence for
LGE was used starting 10 to 15 min after cumu-
lative 0.15-mmol/kg dose of gadolinium dieth-
ylenetriamine pentaacetic acid (Magnevist, Bayer
HealthCare Pharmaceuticals Inc., Wayne, New
Jersey). LGE images were obtained in 8 to 14
matching short-axis (8 mm thick with no gap) and 3
radial long-axis planes.
Human T1 measurements. T1 measurements were
performed with a cine Look-Locker sequence,
similar to a standard inversion time scout sequence,Figure 1. Protocol for Myocardial Fibrosis Imaging
For the myocardial extracellular volume fraction measurement, images
contrast after a total of 0.15 mmol/kg of gadolinium. Late gadolinium en
administration of gadolinium.with a nonslice-selective adiabatic inversion pulse,
followed by segmented gradient-echo acquisition for
17 cardiac phases/times after inversion (TE, 2.5 ms;
TR, 5.5 ms; ﬂip angle, 10; 192  128 matrix;
6-mm slice), spread over 2 cardiac cycles (sampling
frequency of T1 measurements 100 ms pre-contrast
and 55 ms post-contrast, 8-mm slice thickness,
TR >3 RR intervals pre-contrast and 2 RR
intervals post-contrast) (12,13,21). The Look-
Locker sequence was performed in 3 short-axis
slices at the level of the basal, mid, and apical left
ventricle. Each sequence was repeated in the same
LV short-axis slice, once before and 4 to 5 times
after the injection of gadolinium spanning a 30-min
period (Fig. 1). Speciﬁcally, the initial T1 mea-
surement was performed before the administration
of gadolinium. The second T1 measurement was
performed 3 to 4 min after the initial dose of
contrast (0.05 mmol/kg). Immediately after this
second T1 measurement, a second dose of contrast
was given (0.10 mmol/kg), as LGE imaging was
also performed for completeness. The third T1
measurement was performed 3 to 4 min after this
second dose of contrast. The ﬁnal T1 measurement
was performed just before the end of the study, an
average of 30 to 35 min after the initial dose of
contrast. Either 1 or 2 other T1 measurements were
performed after the third measurement and before
the ﬁnal measurement at no pre-set intervals.were acquired pre contrast and as many as 4 to 5 time points post
hancement (LGE) imaging was performed starting 10 to 15 min after
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675Mouse CMR protocol. Twelve male C57BL/6 mice
were imaged on a Bruker 4.7-T CMR imaging
platform. For the CMR study, mice were anes-
thetized with isoﬂurane (induction 4% to 5%;
maintenance 1% to 2% in oxygen from a precision
vaporizer). For the CMR study, mice were placed in
a special cradle, with electrocardiographic electrodes
attached with tape to a front and back paw using
electrode gel to optimize contact. For LV volumes
and mass, measured after contrast administration,
the CMR protocol was built on an electrocardio-
graphically triggered fast gradient-echo FLASH
(fast low angle shot) sequence with the following
imaging parameters: ﬂip angle, 30; TR, 8.85 ms;
TE, 2.36 ms; matrix, spatial resolution, 0.13 
0.15 mm. Cine imaging was obtained in 8 to 12
matching short-axis slices (1 mm thick with no
gap). LV mass and function were measured in a
similar method to the human study. For T1 mea-
surements, we used a Look-Locker sequence with
an adiabatic nonslice-selective inversion pulse and
the following parameters: ﬂip angle, 15; TR,Figure 2. Post-Processing Sequence for Determination of the ECV
For each phase of each slice, the endocardial and epicardial borders of
This was repeated for 1 time point pre gadolinium and 4 to 5 time poin
ventricular cavity. (A) Segments were then annotated 1 through 6 startin
a clockwise direction. Representative curves for the inversion time pre
inversion time. (D) The myocardial extracellular volume fraction for this r
fraction index of 0.32) is then derived by ﬁtting of the R1 (1/T1) in the
hematocrit (Hct). a.u. ¼ arbitrary units.2.2 ms; TE, 1.6 ms; in-plane resolution, 0.13 
0.15 mm, slice thickness, 1 mm; hyperbolic secant
inversion pulse, 6 ms; repetition time per segment,
22 ms; number of averages, 6 (pre-contrast) or
4 (post-contrast). Gadolinium (0.2 mmol/kg) was
diluted in saline solution in a 1:10 ratio and
administered by multiple intraperitoneal injections
in volumes of 200 ml, followed by T1 measurements
no earlier than 5 min after each injection. Contrast
is rapidly (within <1 min) taken up in the blood
and the myocardium after an intraperitoneal injec-
tion, and this avoids the difﬁculty of obtaining tail
vein access.
T1 analysis method. For each Look-Locker se-
quence, the endocardial and epicardial borders of
the LV were traced and divided into 6 standard
segments, and segments were numbered 1 through
6 starting from the anterior right ventricular inser-
tion point and proceeding in a clockwise direction
(Mass Research, Leiden University Medical Center,
Leiden, the Netherlands) (Fig. 2). The signal in-
tensity versus time curves for each segment and thethe left ventricle were traced and divided into 6 standard segments.
ts post gadolinium. A further region of interest was drawn in the left
g from the anterior right ventricular insertion point and proceeding in
(B) and post gadolinium (C) are shown, displaying shortening of the
epresentative healthy volunteer (72 years of age, extracellular volume
myocardium versus the blood and with adjustment for the serum
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676blood pool were used to determine segmental T1
through ﬁtting to an analytical expression for the
inversion recovery and correction for the radio-
frequency pulse alteration of the inversion recovery.
The reciprocal of T1 (R1 ¼ 1/T1) was used to plot
the myocardial R1 against the R1 in the blood pool.
Subsequently, the slope of the association was
calculated by linear regression, using measurement
points with an R1 <3 s 1. The slope of the linear
relationship (the partition coefﬁcient for gadolin-
ium, lGd) was based on an extension of the previ-
ously used formula:







This formula and the linear model apply to the limit
of fast transcytolemmal water exchange, and to meet
this condition, only data points with R1 in blood
<3.0 s 1 were used for the linear regression ﬁts.
From the slope of this relationship, the myocardial
ECV for all 6 myocardial segments was quantiﬁed,
as reported previously (12,13), by multiplying each
of the segmental lGd by (1  hematocrit in percent/
100) (Fig. 2). A global myocardial ECV for each
healthy volunteer was then calculated by averaging
the 6 myocardial segmental values from the mid-LV
short-axis slice.
Mouse blood pressure measurement. Blood pres-
sure was measured in all mice by tail-cuff manom-
etry using a CODA-3 noninvasive blood pressure
monitoring system (Kent Scientiﬁc, Torrington,
Connecticut). The mice were placed in a plastic tube
restrainer, occlusion and volume-pressure recording
cuffs were placed over their tails, and the mice were
allowed to adapt to the restrainer for 30 min before
initiating the blood pressure measurement protocol.
After the adaptation period, blood pressure was
measured for 5 acclimation cycles followed by
10 measurement cycles. Mice were warmed by
heating pads during the acclimation cycles to ensure
sufﬁcient blood ﬂow to the tail. The animals were
monitored closely throughout the measurement
protocol, individually heated or cooled as necessary,
and removed from the restraint as soon as possible
on completing the measurement protocol. All
measurements were taken in the afternoon.
Histological analysis. Hearts from all imaged mice
were excised and ﬁxed in formalin solution for his-
tological analysis. Short-axis cuts (w1-mm thick-
ness) of formalin-ﬁxed tissue were processed and
embedded in parafﬁn using standard histological
preparations. Mouse myocardial sections were taken
of the entire face of a slice, including the septum, LVfree wall, and right ventricular wall. The determi-
nation of the collagen volume fraction of mice was
performed for a mid-level short-axis slice at the same
level as the T1 measurement sequences. Sections of
w5 mm in thickness were stained with Masson’s
trichrome and viewed under polarized light using a
20 objective. Fifteen to 20 representative areas
were chosen in each heart for collagen volume frac-
tion analysis. The Spectrum Analysis algorithm
package and ImageScope analysis software (version
9, Aperio Technologies, Inc., Vista, California) were
applied to quantify histochemical staining. The
fraction of collagen volume is calculated by counting
the number of pixels occupied by the stained region
and dividing this count by the number of pixels
occupied by the entire section.
Statistical analysis. Continuous data are presented
as mean  SD. Continuous data in mice were
compared using an independent Student t test.
Continuous data in humans were compared using
analysis of variance and corrected using a Bonferroni
correction. We assessed the interobserver and
intraobserver variability in a randomly selected
group of 16 volunteers. We also aimed to test the
repeatability of the ECV measurement when sepa-
rated by <3 months. We measured the test-retest
characteristics in 5 randomly selected volunteers by
repeating the measurement of the myocardial ECV
within 1 month. Comparison of the interobserver
and intraobserver characteristics of the myocardial
ECV were made using Bland-Altman plots and
determination of the 95% limits of agreement
between methods. We determined the intraclass
correlation coefﬁcients for the interobserver, intra-
observer, and test-retest absolute agreements of the
ECV. To test whether the addition of multiple
post-contrast measurements of T1 could reduce the
variability of the ECV measurement, we compared
the variances of the ECV when measured using a
single post-contrast T1 and 3 post-contrast T1
values, in combination with a pre-contrast T1 value
(for both cases). Comparison of the SDs of ECV
from a single post-contrast T1 measurement and
the ECV from 3 post-contrast T1 measurements
was made using an F-statistic. We also determined
the association between the myocardial ECV and
other cohort characteristics using a Pearson corre-
lation. We performed a multivariable analysis in
humans of the ECV versus age, body surface area,
LV mass, and heart rate. The Akaike Information
Criterion was used as the criterion for selection
of the best prognostic model for a level of signiﬁ-
cance of 0.05 (22). A 2-sided p value of <0.05
was deemed signiﬁcant. Regression analysis was
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677performed in R-statistics software (version 2.9.0,
R Foundation, Vienna, Austria); SAS software was
used for all other statistical analysis (version 9.1,
SAS Institute Inc., Cary, North Carolina).
RESULTS
Baseline parameters in healthy volunteers. Overall,
32 volunteers were recruited, and all were included
in the analysis. There were 18 women (56%) and
14 men. The mean age of volunteers was 49 
15 years (range 21 to 72 years). The average body
mass index was 26 6 kg/m2, systolic blood pressure
was 120  11 mm Hg, diastolic blood pressure was
74  7 mm Hg, heart rate was 68  11 beats/min,
and hematocrit was 42  3% (Table 1).
Baseline CMR parameters in healthy volunteers.
Baseline CMR parameters are presented in Table 1.
In brief, the mean LV end-diastolic volume was
133  29 ml, indexed LV mass was 45  7 g/m2,
right ventricular end-diastolic volume was 131 
31 ml, indexed maximal left atrial volume was 33 
10 ml/m2, right ventricular ejection fraction was
53  4%, and LV ejection fraction was 64  7%.
Myocardial ECV in healthy volunteers. LGE was not
identiﬁed in any normal volunteer. The number





Mean age, yrs 49  15 31
Female 18 (56) 5
Body mass index, kg/m2 26  6 24
Systolic blood pressure, mm Hg 120  11 111
Diastolic blood pressure, mm Hg 74  7 72
Heart rate, beats/min 68  11 63
LVEDV, ml 133  24 142
LVESV, ml 48  15 50
Septal wall thickness, mm 8  1 6
Lateral wall thickness, mm 7  1 7
LV mass index, g/m2 45  7 41
RVEDV, ml 131  31 154
RVESV, ml 61  10 76
Indexed maximum LA volume, ml/m2 33  10 29
LVEF, % 64  7 64
RVEF, % 53  4 51
ECV 0.28  0.03 0.25
Values are mean  SD or n (%).
ECV myocardial extracellular volume fraction derived from quantitative T1 m
end-diastolic volume; LVEF left ventricular ejection fraction; LVESV left ven
RVEF right ventricular ejection fraction; RVESV right ventricular end-systolic vo4 (mean, 3.5) in all human studies. We measured
the myocardial ECV in 6 segments in 3 slices of the
LV (basal, mid-ventricular, and apical). The average
myocardial ECV was 0.28  0.03 (range 0.23 to
0.33). There was no difference in the myocardial
ECV between basal, mid, or apical slices in healthy
controls (0.27  0.02 vs. 0.28  0.03 vs. 0.28 
0.03, basal, mid, and apical slices, respectively;
p ¼ 0.34 for trend). There was also no difference
between segments within a slice; for example, the
mid-ventricle was split into 6 segments (0.28 
0.04, 0.28  0.04, 0.28  0.04, 0.29  0.04, 0.29 
0.03, 0.29  0.03, segments 1 through 6, respec-
tively; p ¼ 0.38 for trend). We measured the
interobserver and intraobserver variability in 15
randomly selected studies. The mean interobserver
difference was 0.02  0.01 (95% conﬁdence interval
[CI]: 0.005 to 0.005) (Fig. 3A), the mean intra-
observer difference was 0.01  0.01 (95% CI:
0.005 to 0.005) (Fig. 3B), and the test-retest
difference was 0.01  0.01 (95% CI: 0.015 to
0.015). The intraclass coefﬁcients for the intra-
observer, interobserver, and the test-retest mea-
surements of the ECV were 0.94 (n ¼ 16, 95% CI:
0.84 to 0.98), 0.93 (n ¼ 16, 95% CI: 0.80 to 0.98),
and 0.95 (n ¼ 5, 95% CI: 0.52 to 0.99), respectively.






(n [ 11) p Value
 7 51  5 65  5 <0.001
(50) 6 (55) 7 (70) 0.23
 4 28  6 27  6 0.27
 11 121  11 125  6 0.31
 5 72  8 74  5 0.72
 13 68  8 68  9 0.56
 23 141  20 118  27 0.12
 17 51  9 43  15 0.24
 1 7  1 8  1 0.24
 1 7  1 7  1 0.24
 9 46  4 47  8 0.23
 27 138  24 113  25 0.009
 8 59  8 55  11 0.015
 9 33  10 37  8 0.12
 9 64  14 63  7 0.66
 5 56  7 51  5 0.53
 0.02 0.27  0.03 0.31  0.02 <0.001
easurements; LA left atrial; LV left ventricular; LVEDV left ventricular
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Figure 3. Bland-Altman Plots
The 95% limits of agreement between 2 observers (A) and within a single observer (B) for 15 randomly selected volunteers is shown.
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678groups did not differ in age (51  14 years vs. 47 
15 years, p ¼ 0.30). There were no difference in the
myocardial ECV in males compared with females
(0.28  0.03 vs. 0.27  0.03, males vs. females, p ¼
0.20). To test whether the use of multiple T1
measurements post-contrast reduced measurement
variability, we compared the measurement vari-
ability of the ECV using a single T1 measurement
compared with using 3 post-contrast T1 measure-
ments. We found using a single measurement was
associated with a higher SD of 0.041 than using 3
post-contrast T1 measurements, which had as SD
of 0.026 (p ¼ 0.02).
Association between the ECV and other variables in
healthy volunteers. The myocardial ECV increased
with age (r ¼ 0.74, p < 0.001). To test the presence
of confounders, we tested the association between
pre-contrast blood pool T1 values and heart rate and
age. There was no association between the heart rate
and the ECV (r ¼ 0.02) and age and pre-contrast
blood pool T1 values (r ¼ 0.09). We performed a
multivariable analysis for the ECV versus age, body
surface area, LV mass, and heart rate. Using this
analysis, we got a ﬁnal multivariable model of the
following in which age had the strongest indepen-
dent association with the ECV (t value ¼ 6.00, p <
0.0001). The entire cohort was split into 3 age
ranges of younger than 40, 40 to 60, and older than
60 years of age. There was a graded increase in the
myocardial ECV from 0.25  0.02 versus 0.27 
0.03 versus 0.31  0.02 with increasing age ranges
(p < 0.001) (Fig. 4A). There was no association
between the myocardial ECV and heart rate
(r ¼ 0.07). There was an association between themyocardial ECV and indexed LV mass (r ¼ 0.52,
p < 0.01) (Fig. 4B) and maximal left atrial volume
index (r ¼ 0.67, p < 0.001).
Comparison of juvenile and aged mice. As expected,
body weight, LV volumes, mass, and stroke volumes
were increased in aged mice compared with juvenile
mice (Table 2) (23). Both systolic and diastolic blood
pressure was unchanged in juvenile compared with
aged mice. The myocardial ECV was higher in older
compared with younger mice (0.22  0.02 vs.
0.30  0.02, juvenile vs. aged, p < 0.001) (Fig. 5A).
Hearts were harvested immediately after the CMR
study, and sections were stained using Masson’s
trichrome. There was an increase in myocardial
ﬁbrosis in aged mice compared with juvenile mice
(2.1  1.0% vs. 5.8  1.0%, young vs. old mice, p <
0.001). There was a strong association between the
myocardial ECV and LV mass (r¼ 0.81, p< 0.001)
and the extent of myocardial ﬁbrosis (r ¼ 0.93, p <
0.001) (Fig. 5B). Representative images are shown
from a juvenile and aged mouse (Figs. 5C to 5F).
D I SCUSS ION
In this study, we measured the myocardial ECV in
healthy volunteers and mice using a quantitative T1
technique. The myocardial ECV averaged 0.28 
0.03 and ranged from 0.23 to 0.33 in humans. In
humans, there was a correlation between myocardial
ECV, age, and LV mass. Importantly, there was a
consistent increase in the myocardial ECV with
increasing age in both volunteers and mice. In mice,
we were able to test whether the increase in the
myocardial ECV with age was associated with
A B
Figure 4. Association Between the Myocardial ECV and Age in Healthy Volunteers
There was a strong association between the myocardial extracellular volume fraction (ECV) and age (A) and the myocardial ECVF with indexed
left ventricular (LV) mass (B). {p < 0.001 vs. age range 40 to 60 years; *p < 0.001 vs. age range >60 years).




(n [ 8) p Value
Body weight, g 20  1 38  2 <0.001
Heart rate, beats/min 496  41 455  44 0.14
Systolic blood pressure, mm Hg 109  4 114  4 0.08
Diastolic blood pressure, mm Hg 80  4 81  3 0.60
LVEDV, ml 40  9 70  8 <0.001
LVESV, ml 12  5 25  4 <0.001
LV mass, mg 57  4 119  16 <0.001
LVEF, % 70  5 64  6 0.09
Cardiac output, ml/min 14  2 16  4 0.22
Stroke volume, ml 31  9 45  8 0.02
ECV 0.22  0.02 0.30  0.02 <0.001
Values are mean  SD.
Abbreviations as in Table 1.
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679expansion of the extracellular matrix. In mice, there
was a strong association between the increase in
the myocardial ECV and histological evidence
of increasing myocardial ﬁbrosis. The range of
myocardial ECV in mice was similar to the range
observed in our human volunteers. These data
suggest that aging is associated with an increase in
the myocardial extracellular volume that is detect-
able using T1 measurements.
These data on noninvasive quantiﬁcation of the
myocardial ECV are both additive to and an
extension of previously published work (9,12
15,24 26). Klein et al. (25) used a Look-Locker
sequence to calculate a volume of distribution of
gadolinium, a myocardial ECVF, in patients with
an ischemic cardiomyopathy. They found that the
myocardial ECVF was elevated in areas of scar
compared to “normal” myocardium. Lee et al. (26)
measured myocardial T1 values at 3-T in normal
healthy volunteers using a different technique
(modiﬁed Lock-Locker inversion recovery [MOLLI]
technique) and calculated an average ECV of 27%.
Some differences exist between the methods used in
this and previous studies. First, because we rely on
the change of R1 with time, and not on absolute T1
or R1 values, the results are relatively independent
of ﬁeld strength. The technique adjusts for the
blood levels of gadolinium by relating the change in
R1 in the myocardium and to the corresponding
R1 change in blood. Therefore, the estimate of
ECV is gadolinium dose independent and largely
independent of the clearance of gadolinium from
the blood pool, as proven by a previous comparisonof the infusion and bolus techniques for ECV
quantiﬁcation (21). The Look-Locker technique
used here for T1 imaging allows image acquisition
within a single breath-hold per slice, while main-
taining a TI resolution of 50 ms for post-contrast
measurement acquisition. The protocol used, with
at least 3 post-contrast T1 measurements at 3 slice
levels, extends a regular CMR study by 5 to 10 min.
This method does not depend on the exact timing
of the T1 measurement after infusion of gadolinium
because multiple measurements of T1 times are
recorded repeated multiple times over the course of
the CMR study to optimize the accuracy of the
partition coefﬁcient determination. A previous
Figure 5. The Myocardial ECV in Juvenile and Aged Mice
Juvenile (4 weeks) and aged (48 weeks) mice underwent a cardiac magnetic resonance (CMR) study. After the CMR study, mice were
euthanized, and cardiac sections were harvested for measurement of myocardial ﬁbrosis using Masson’s trichrome. (A) The myocardial
extracellular volume fraction (ECV) was higher in aged mice than juvenile mice (0.22  0.02 vs. 0.30  0.02, p < 0.001). Histological analysis
revealed an increase in the extent of myocardial ﬁbrosis in young versus older mice (2.1  1.0% vs. 5.8  1.0%, young vs. old mice, p < 0.001).
(B) There was a strong association between the myocardial ECV and the extent of myocardial ﬁbrosis (r ¼ 0.93, p < 0.001). Representative
images are shown from a juvenile mouse (C, E) and an aged mouse (D, F) showing normal myocardial architecture stained in red with
interwoven patches of myocardial ﬁbrosis stained blue.
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680report on the measurement of the partition coefﬁ-
cient for gadolinium contrast in human myocardium
(lGd), noted a relatively large range for lGd, corre-
sponding to a 50% to 60% change in ECV,
assuming a constant hematocrit (21). The adjust-
ment of the partition coefﬁcient for gadolinium by
multiplication with (1-hematocrit) to determine the
myocardial ECV may be 1 reason for the reduced
variability in this study (21). Furthermore, >2 T1measurements were used in combination with a
linear regression ﬁt for all values with R1 in blood
<3.0 s 1, which reduces variability compared with a
2-point method.
This work has potential clinical and research
implications. Aging is associated with a progressive
increase in ventricular stiffness and impaired dia-
stolic function (27,28). This age-related impair-
ment of diastolic function is associated with the
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681development of heart failure and increased mortality
(29,30). Similar to published data in patients with
known or suspected cardiovascular disease (14), we
found that age was associated with an increase in the
myocardial ECV in healthy human volunteers in
this study. Key differences may relate to the study
cohort. We speciﬁcally selected healthy subjects free
of cardiovascular disease, hypertension, diabetes,
and sleep apnea, with a normal blood pressure and a
structurally normal heart. However, data are con-
ﬂicting regarding the relationship between the ECV
and age, and the association between the ECV and
LV mass (31). We note that in our study there was a
signiﬁcant positive correlation between ECV and
LV mass, but in a multivariate regression model for
the ECV, there was no signiﬁcant association be-
tween ECV and LV mass, if ECV is simultaneously
adjusted by age and sex, suggesting that the asso-
ciation between the ECV and LV mass may be
confounded by age. Although limited data exist
regarding the association between the ECV and LV
mass, there are signiﬁcant supportive data detailing
the strong association between myocardial ﬁbrosis
as measured using LGE-based techniques and
increased LV mass (32,33). We also show, in wild-
type mice, the pathological correlative ﬁnding of an
increase in myocardial ﬁbrosis. These mice data are
consistent with published animal work demon-
strating an association between aging and myocar-
dial ﬁbrosis (34,35). Human pathological data are
conﬂicting, but signiﬁcant supportive data exist
suggesting that aging is associated with expansion of
the extracellular space and an increase in interstitial
ﬁbrosis and appearance of small foci of replacement
ﬁbrosis in men and women (36 38). Apoptosis, an
enlargement of myocyte size, and extracellular ma-
trix proliferation are other distinctive age-associated
changes in myocardial structure. Measurement of
the myocardial extracellular volume may provide an
early marker of these adverse changes in myocardial
tissue structure and may precede overt impairment
of ventricular function. To support this, we also
found an association between the myocardial ECV
and left atrial volume, the latter a commonly used
index of diastolic function. However, further work
will help determine the natural progression of
changes in myocardial structure and function and
whether the CMR-detected increase in the myocar-
dial ECV is associated with an increased risk of
heart failure.
A robust marker for expansion of the extracel-
lular volume may have extended applicability in
cardiovascular monitoring (39). Previous work
found a similar normal range for myocardial ECV(14,26) and showed that the ECV can reliably
differentiate between normal and abnormal myo-
cardium (14,25). Flett et al. (9) tested whether
serial T1 measurements were an index of patho-
logical expansion of the extracellular space. In that
study, they found a strong association between
the ECV and the extent of myocardial ﬁbrosis in
patients with aortic stenosis and hypertrophic car-
diomyopathy. Finally, Iles et al. (10) found that post-
contrast T1 correlated with histological evidence of
myocardial ﬁbrosis in patients with heart failure
and extended these ﬁnding by showing an associa-
tion with diastolic function. In contrast, the present
study focused on a cohort of volunteers without any
history or signs or symptoms of cardiac disease.
Study limitations. This study has to be interpreted
within the context of the design format. Image
acquisition only extends an average clinical study by
5 min; however, the interpretation currently requires
manual tracing of the endocardial contours for 16 to
17 phases from a cine image at as many as 5 time
points. We performed a total of 4 to 5 T1 mea-
surements, a pre-gadolinium measurement and 3 to
4 post-gadolinium measurements after a cumulative
dose of gadolinium of 0.15 mmol/kg. However,
unlike standard clinical practice, the dose of gado-
linium was split. Although we acknowledge this as a
limitation of the external application, we do not
believe that this would likely yield a signiﬁcant
difference in the ECV compared with a single dose
of gadolinium. Pathological validation of the CMR-
derived ECV as a noninvasive correlate for myo-
cardial collagen content has already been published
(19); we did not perform endomyocardial biopsies in
our healthy volunteer population or provide serum
surrogates for collagen turnover. To attempt to
address this limitation, we tested the myocardial
ECV in mice and found that, similar to humans,
there was an age-related increase in the myocardial
ECV. However, important biological differences
have been reported regarding the effect of aging in
rodents compared with humans that we did not
address (40). Other techniques are also available for
measuring myocardial T1. These techniques include
the MOLLI and the shortened modiﬁed Lock-
Locker inversion recovery (ShMOLLI) methods.
Techniques such as MOLLI and ShMOLLI are
acquired in the same quiescent window of several
cardiac cycles as opposed to data acquisition over the
entire cardiac cycle of the Look-Locker cine
sequence used in this study. Also, although the
acquisition time for the raw data is similar between
ShMOLLI and the Look-Locker sequence, the
analysis time is faster for either the ShMOLLI or
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682the MOLLI method (15,41). Data from Kawel
et al. (24) using the MOLLI technique with gad-
olinium diethylenetriamine pentaacetic acid and
gadolinium benzyl oxypropionic tetraacetic acid
have shown that the relaxivity of the contrast agent
may play a role in the ECV determination. It is
known that the relaxivity of gadolinium benzyl
oxypropionic tetraacetic acid depends on protein
concentration, a property that can be potentially a
confounding factor in the determination of the
extracellular volume fraction. We did not perform
echocardiography in healthy controls to determine
whether an association existed between measure-
ments of diastolic function and the myocardial
ECV. Furthermore, although all controls were free
of cardiovascular disease by history, had a normal
blood pressure, and had a structurally normal heart
on CMR, we did not perform 12-lead electrocar-
diography to further add to this assessment. How-
ever, we did ﬁnd an association between the
myocardial ECV and left atrial volume with an in-
crease in the ECV being associated with larger left
atrial volume suggesting a potential link. Multiple
pathological processes such as edema and inﬁltra-
tion can expand the extracellular matrix and mea-
surement of the myocardial ECV alone is unable todifferentiate between these processes and hence
must be interpreted within a clinical context.
CONCLUS IONS
In summary, ECV is a novel and potentially useful
index for quantiﬁcation of the myocardial ECV. In
humans, the myocardial ECV increases with age,
is associated with LVmass and left atrial volume, and
has reliable test characteristics. In mice, the myocar-
dial ECV also increases with age, is also associated
with LV mass, and is strongly associated with the
extent of myocardial ﬁbrosis. Further work will need
to be done to test the application of this technique in
patients with cardiovascular disease associated with
the development of myocardial ﬁbrosis.
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